Hello there

Stille have a 180+ year long history of helping surgeons achieve surgical perfection. The company’s significance as to the impact to surgeons and their patients throughout history should not be understated. Our continued commitment to quality and innovation coupled with underlying long-term market trends makes the company a strong investment case for potential shareholders.

Financial Calendar

Financial Targets

Organic sales growth

> 10%

EBITDA

> 25%

NET DEBT/EBITDA
(long-term)

< 3

Target Fulfilment

Organic growth
EBITDA
Net debt/EBITDA R12

Cap Table

Why invest in Stille

1

PRODUCT LEADERSHIP

Premium offering within cardiac, cardiovascular, micro, neuro, plastic, and spine surgical disciplines

2

MARKET EXPANSION

Continuous growth and sales development with strategic partners. Maintain and develop strong global sales and service channels.

3

OPERATIONAL EXCELLENCE

Efficient and scalable manufacturing processes. Continuous improvement of operational expenditures. Continuous investment in R&D.

4

ACQUISITIONS

Additional growth through strategic acquisitions of products & sales channels.

Investor Relations Contacts

Torbjörn Sköld

President & CEO

torbjorn.skold@stille.se

Nicklas Carlén

CFO

nicklas.carlen@stille.se